Immunovant (Nasdaq:IMVT) - Aktienkurs, Nachrichten und Analyse

IMVT Aktienübersicht

Immunovant, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt monoklonale Antikörper für die Behandlung von Autoimmunerkrankungen.

Über das Unternehmen

IMVT fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Belohnungen

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Signifikante Insiderverkäufe in den letzten 3 Monaten

Die Aktionäre wurden im vergangenen Jahr verwässert

Immunovant, Inc. Wettbewerber

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Merus

NasdaqGM:MRUS

US$3.7b

RayzeBio

NasdaqGM:RYZB

US$3.7b

Crinetics Pharmaceuticals

NasdaqGS:CRNX

US$3.5b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Immunovant
Historical stock prices
Current Share Price	US$26.19
52 Week High	US$45.58
52 Week Low	US$18.16
Beta	0.72
1 Month Change	-14.69%
3 Month Change	-17.04%
1 Year Change	31.74%
3 Year Change	136.16%
5 Year Change	163.22%
Change since IPO	163.22%

Aktuelle Nachrichten und Updates

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Aktionärsrenditen

	IMVT	US Biotechs	US Markt
7D	4.3%	-1.8%	1.6%
1Y	31.7%	5.5%	22.3%

Preisvolatilität

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Average Weekly Movement	6.1%
Biotechs Industry Average Movement	10.6%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.8%

Volatilität im Zeitverlauf: IMVTDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 15% auf 6% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	207	Pete Salzmann	immunovant.com

Immunovant, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt monoklonale Antikörper für die Behandlung von Autoimmunerkrankungen. Das Unternehmen entwickelt Batoclimab, einen neuartigen, vollständig humanen monoklonalen Antikörper, der auf den kristallisierbaren Rezeptor des neonatalen Fragments abzielt, zur Behandlung von Myasthenia gravis, Schilddrüsenerkrankungen, chronisch entzündlicher demyelinisierender Polyneuropathie, Morbus Basedow und warmer autoimmuner hämolytischer Anämie. Immunovant, Inc. hat seinen Sitz in New York, New York.

Immunovant, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Immunovant im Vergleich zum Marktanteil des Unternehmens?
IMVT grundlegende Statistiken
Marktanteil	US$3.91b
Gewinn(TTM)	-US$259.34m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-14.7x

Kurs-Gewinn-Verhältnis

Ist IMVT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
IMVT Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$259.34m
Umsatz	-US$259.34m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.78
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich IMVT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

IMVT Aktienübersicht

Belohnungen

Risikoanalyse

Immunovant, Inc. Wettbewerber

NasdaqGS:TPTX

US$3.8b

NasdaqGM:MRUS

US$3.7b

NasdaqGM:RYZB

US$3.7b

NasdaqGS:CRNX

US$3.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Recent updates

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Price target decreased to US$10.78

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Price target decreased to US$11.25

Chief Medical Officer recently sold US$222k worth of stock

Price target decreased to US$12.25

Immunovant, Inc. Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Independent Director recently bought US$150k worth of stock

Independent Director recently bought US$54k worth of stock

Price target decreased to US$19.86

Erträge & Einnahmen